Baxter International Inc (BAX) 43.85 $BAX Baxter

New Post Public Reply Private Reply Replies (0) Message Board

Jun 25, 2016 at 9:21 AM

Baxter International Inc (BAX) 43.85 $BAX

Baxter International, Fluor, BlackRock, Legg Mason and Invesco highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 8:30AM CDT
Baxter International, Fluor, BlackRock, Legg Mason and Invesco highlighted as Zacks Bull and Bear of the Day
BLK: 332.51 (-24.34), BAX: 43.85 (-2.11), IVZ: 25.57 (-4.05), FLR: 48.78 (-4.20), LM: 29.49 (-3.12)

Genomic Health: Can the Liquid Biopsy Test Boost Margins?
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:50AM CDT
Genomic Health (GHDX) recently launched a next-generation sequencing blood-based mutational panel -- Oncotype SEQ Liquid Select.
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), GHDX: 26.11 (-0.48)

FDA Okays Trial for Medtronic's MRI-Guided Epilepsy Device
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 6:31AM CDT
With surgical procedures gaining ground in the treatment of drug-resistant epilepsy, the FDA go-ahead will expand Medtronic's (MDT) footprint in the billion-dollar neurosurgical market.
ICUI: 106.49 (-1.64), MDT: 83.26 (-2.51), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40)

Bull of the Day: Baxter International (BAX)
Jeremy Mullin - Zacks Investment Research - Fri Jun 24, 6:00AM CDT
Bull of the Day: Baxter International (BAX)
BAX: 43.85 (-2.11)

GNC Gains as Buyout Rumors of Vitamin Shoppe Resurface
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:32AM CDT
The Vitamin Shoppe buyout rumor first buzzed in immediately after GNC Holdings Inc.'s (GNC) earnings call in the last quarter.
BSX: 22.37 (-0.60), HLF: 57.50 (-4.83), BAX: 43.85 (-2.11), GNC: 24.50 (-1.22)

Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 106.49 (-1.64), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), HOLX: 34.11 (-1.51)

Stryker (SYK) Hits 52-Week High on Positive FY16 View
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:14AM CDT
Share price of Stryker Corp (SYK) rallied to a new 52-week high of $116.99 on Jun 20.
MASI: 50.96 (-1.42), BAX: 43.85 (-2.11), CRY: 11.55 (-0.39), SYK: 116.59 (-1.79)

Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), QGEN: 21.01 (-1.38)

Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 106.49 (-1.64), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), HOLX: 34.11 (-1.51)

AmSurg, Envision Healthcare Set to Merge by 2016-End
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:47AM CDT
Envision shareholders will own 53% of the combined entity while AmSurg (AMSG) shareholders will have 47%.
AMSG: 79.15 (-2.52), EVHC: 25.99 (-0.69), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40)

Hill-Rom Holdings (HRC) Looks Good: Stock Adds 5.4% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:40AM CDT
Hill-Rom Holdings, Inc. (HRC) saw its shares rise almost 7% in the last trading session.
BAX: 43.85 (-2.11), HRC: 50.27 (-1.79)

Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), ILMN: 138.91 (-7.68), GHDX: 26.11 (-0.48)

Zacks.com featured highlights: Cimpress, Ubiquiti Networks, Baxter International, Home Depot and Electronic Arts
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:30AM CDT
Zacks.com featured highlights: Cimpress, Ubiquiti Networks, Baxter International, Home Depot and Electronic Arts
HD: 126.40 (-1.89), UBNT: 38.59 (-1.55), EA: 73.21 (-2.84), BAX: 43.85 (-2.11), CMPR: 93.17 (-4.82)

Data Show Sigma Spectrum Infusion System Users Achieved 97 Percent Drug Library Compliance Rate within the First Month of Implementation(1)
BusinessWire - Thu Jun 16, 7:15AM CDT
Baxter International (NYSE: BAX) is committed to enhancing patient safety during medication delivery, and today highlighted compliance data showing facilities that implemented Sigma Spectrum Infusion Systems achieved an overall average of 97 percent drug library compliance within the first 30 days of implementation.(1) Consistent use of drug libraries is critical to help identify and prevent potentially harmful medication infusion errors. Each year in the United States, there are an estimated 1.2 million preventable harmful medication errors associated with injectable medications.(3)
BAX: 43.85 (-2.11)

Qiagen???s QIAsure Test to Determine Cervical Cancer Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:33AM CDT
Qiagen's (QGEN) QIAsure accurately stratifies cervical cancer risk, which offers highly sensitive and specific results for patients and clinicians.
BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), QGEN: 21.01 (-1.38), NUVA: 57.93 (-0.93)

Boston Scientific: NICE Backs GreenLight XPS for BPH Cure
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:01AM CDT
As per NICE's estimates, broad adoption of Boston Scientific's (BSX) GreenLight therapy over TURP can lead to savings of up to ??3.2 million annually for the National Health Service (NHS).
BSX: 22.37 (-0.60), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40), NUVA: 57.93 (-0.93)

5 Efficient Stocks to Revitalize Your Portfolio
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 5:35AM CDT
Investing in efficient companies can yield healthy returns irrespective of market conditions.
HD: 126.40 (-1.89), UBNT: 38.59 (-1.55), EA: 73.21 (-2.84), BAX: 43.85 (-2.11), CMPR: 93.17 (-4.82)

Boston Scientific: Restructuring Plan, Global Growth Impress
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 6:14AM CDT
On Jun 13, 2016, we issued an updated research report on Boston Scientific Corporation (BSX).
BSX: 22.37 (-0.60), ICUI: 106.49 (-1.64), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40)

Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 22.37 (-0.60), HAE: 28.76 (-1.41), BAX: 43.85 (-2.11), LMAT: 14.42 (-0.40)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Better Home & Finance Tumbles: Legal Woes and Losses Mount

Better Home & Finance's Financial Freefall The rollercoaster of stock markets sees plenty of ups and downs, but when you tack on a securities class action, it’s more like getting stuck on a loop. That’s exactly where Better Home & Finance (NASDAQ: BETR) finds itself after the wheels came off in their Q1 2026 report. A gut-wrenching 75% jump in their net loss tells you...

Cytrellis Boosts Aesthetics Training With Miami Partnership

Cytrellis Partners with University of Miami The announcement from Cytrellis Biosystems is drawing some attention. The company's jumped into a new partnership with the University of Miami School of Nursing and Health Studies, looking to jazz up their Aesthetic Medicine Certificate Program. The kicker here is the introduction of Cytrellis' ellacor® system, a fancy bit of...

Skechers Faces Shareholder Lawsuit: Must Act by Dec 21

Skechers Shareholders Stirring Over Lawsuit A fresh wave of legal antics is crashing at the shores of Skechers U.S.A., Inc. (NYSE: SKX) as frustrated shareholders mobilize against the footwear juggernaut. We're talking about a class action lawsuit here, folks, aimed at shaking down some clarity—or maybe just some cold, hard cash—from this bruiser over some sketchy...

CapCut's AI Growth Combines Video, Image, and Music Tools

CapCut's Recognition in the Creative AI Space The shift towards comprehensive creative platforms is taking the tech world by storm, and CapCut's latest nod from Software Experts is turning heads in 2026 with its ambitious integration. Touted for its versatility, CapCut serves creative projects that need an amalgamation of video, image, and audio elements. Tackling the...

Cerebras Faces Durability Allegations: Investor Alert

Cracks in Cerebras' Processor Promises? When you dance with high-stakes tech stocks, sometimes you end up stepping on a few toes. This seems to ring true as Cerebras Systems (CBRS) dances its way into hot water. Allegations from Culper Research suggest their fancy AI processors, which are supposed to be the poster children of reliability, might bow out early. Digging...

Orbis International to Boost Global Eye Health Efforts

Pledge for Vision In a world where a staggering number of folks wrestle with avoidable vision issues, Orbis International is stepping up to the plate with ambitions that feel as bold as they are necessary. Orbis is pouring a significant $32 million into its mission to beef up eye health systems, train a small army of professionals, and apply AI in eye care. Their big bet...

Phrontline's TJ101 Gains Momentum in Cancer Clinical Trials

Encouraging Signs from Phrontline's TJ101 ADC Trials In the high-stakes race to outsmart cancer, Phrontline Biopharma is banking on TJ101, their star investigational bispecific antibody-drug conjugate (ADC). The recent results shared at the ESMO Congress 2026 are stirring up quite a bit of chatter. Urothelial Carcinoma and Beyond Now, picture this: six of eight evaluable...

Green Methanol: A $20.11B Market by 2032 Excites

The Green Methanol Boom Folks, the money's about to get greener—greener methanol, that is. We’re talking about a market that’s set to explode from a humble $3.46 billion in 2026 to a jaw-dropping $20.11 billion by 2032. With a hefty CAGR of 34.1%, it seems like investors might want to buckle up for a bullish ride in this eco-friendly venture. Why Green Methanol?...

Epicurean Expeditions Mix Food Joy with Ocean Luxury

Atlas Expands Culinary Cruise Horizons in 2027 Now here's a twist for you—cuisine meets cruise in a hefty blend of sail, chew, and swirl. Atlas Ocean Voyages is practically throwing a gourmet party on water with their 2027 Epicurean Expeditions. They're unfurling the sails alongside chef heavyweights like Crista Luedtke and wine maestro Anthony Giglio. Imagine a cruise...

Gate's Strong Q3: Sales Growth & Rising Margins

Solid Performance Boosts Confidence Gates Industrial came out swinging with their third-quarter results for 2026, showing some financial prowess that would make even the skeptics raise an eyebrow. Net sales climbed to a hefty $903.6 million, advancing 5.6% from the same time last year. It's not just smoke—core sales jumped 5.5%, signaling they're doing a bit more than...